Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

TCGA-86-8076-01A-31R-2241-07

— · cohortA1

8086de6d-6301-51dc-a0d7-6a729b86fdd5

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortA1
subtype
cohortA1
age_years
42

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.470
  • INTERFERON_GAMMA_RESPONSE+0.350
  • IL6_JAK_STAT3_SIGNALING+0.310
  • INFLAMMATORY_RESPONSE+0.270
  • INTERFERON_ALPHA_RESPONSE+0.260
  • COMPLEMENT+0.230
  • KRAS_SIGNALING_UP+0.230
  • TNFA_SIGNALING_VIA_NFKB+0.170
  • PANCREAS_BETA_CELLS+0.160
  • IL2_STAT5_SIGNALING+0.150

Top 10 suppressed

  • E2F_TARGETS-0.670
  • G2M_CHECKPOINT-0.630
  • MTORC1_SIGNALING-0.460
  • CHOLESTEROL_HOMEOSTASIS-0.440
  • MITOTIC_SPINDLE-0.380
  • DNA_REPAIR-0.360
  • MYC_TARGETS_V2-0.360
  • MYC_TARGETS_V1-0.340
  • GLYCOLYSIS-0.300
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.290

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR13780258
lung-landscapes@6
—cohortMD20.883
2TCGA-44-2661-01A-01R-1107-07
lung-landscapes@6
—cohortA10.871
3SRR8518255
breast-umap@18
—D0.870
4TCGA-44-2657-01A-01R-1107-07
lung-landscapes@6
—cohortA10.868
520050035.Her2HRneg
breast-umap@18
—D0.866
6SRR8518296
breast-umap@18
—A0.861
7SRR8518166
breast-umap@18
—D0.852
8TCGA-55-7725-01A-11R-2170-07
lung-landscapes@6
—cohortMD20.847
9X14ed6d5a.d8f1.41aa.93e1.fba99596f5fd
lung-landscapes@6
—cohortA10.846
10SRR13780265
lung-landscapes@6
—cohortMD20.841

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 17 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.470Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.350Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.310Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.270Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.260Inavolisib— uncovered
COMPLEMENT0.230Inavolisib— uncovered
KRAS_SIGNALING_UP0.230Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.170Inavolisib— uncovered
PANCREAS_BETA_CELLS0.160Cobimetinib— uncovered
IL2_STAT5_SIGNALING0.150Idelalisib— uncovered
BILE_ACID_METABOLISM0.140Inavolisib— uncovered
HEME_METABOLISM0.130Temsirolimus— uncovered
ADIPOGENESIS0.070Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.070Inavolisib— uncovered
COAGULATION0.060Binimetinib— uncovered
FATTY_ACID_METABOLISM0.030Inavolisib— uncovered
UV_RESPONSE_DN0.020Inavolisib— uncovered